Gain Therapeutics (GANX) Change in Accured Expenses (2020 - 2026)

Gain Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $531767.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 52.27% year-over-year to $531767.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 253.33% YoY), while the FY2025 annual figure was -$468606.0, down 270.47% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $531767.0, up from -$785258.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.7 million in Q1 2022, with the low at -$1.9 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is -$46100.0 (2023), against an average of $20907.4.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses soared 50338.17% in 2022, then tumbled 3920.98% in 2024.
• Gain Therapeutics' Change in Accured Expenses stood at -$822482.0 in 2022, then retreated by 24.9% to -$1.0 million in 2023, then soared by 94.35% to -$58070.0 in 2024, then slumped by 1252.26% to -$785258.0 in 2025, then jumped by 167.72% to $531767.0 in 2026.
• Business Quant data shows GANX's Change in Accured Expenses at $531767.0 in Q1 2026, -$785258.0 in Q4 2025, and -$949139.0 in Q3 2025.